Revision of Chapter 7 Contract Manufacture and Analysis

Size: px
Start display at page:

Download "Revision of Chapter 7 Contract Manufacture and Analysis"

Transcription

1 Revision of Chapter 7 Contract Manufacture and Analysis GMP & Market Compliance Information Day, Catherine Neary Inspector Date Insert on Master Slide Slide 1

2 Overview Purpose of revision to Chapter 7 Comparison of ICH & EU GMP Requirements Impact Assessment & Implications of new revision Next Steps 14 October 2010 Slide 2

3 Revision of Chapter 7 EU GMP (1) Contract Manufacture & Analysis EMA concept paper published in October edural_guideline/2009/10/wc pdf Draft revision at the finalisation stage Public consultation before end 2010 Watch for further details 14 October 2010 Slide 3

4 Revision of Chapter 7 EU GMP (2) Purpose of the Revision Reflect the range & extent of modern contracting operations Reflect the increased complexity in modern contracted arrangements Harmonisation with ICH Q10 More prescriptive requirements for outsourced operations Particular emphasis on the contract giver s obligations 14 October 2010 Slide 4

5 ICH Q10 ICH Guidelines can be accessed through the following link: ICH Q10 Pharmaceutical Quality System Guidance on key elements for an effective quality system Complements ICH Q8 Pharmaceutical Development & ICH Q9 Quality Risk Management ICH Q10 (Section 2.7): Management of Outsourced Activities & Purchased Materials 14 October 2010 Slide 5

6 Comparison of ICH & EU GMP Requirements ICH Q10 EU GMP Chapter 7 Applies to all outsourced activities & purchased materials Obligations specific to the Contract Giver Assessment should incorporate QRM principles Specific in the need for prior assessment & audit Requires both responsibilities & communication processes to be defined in contract Specific in the need for periodic review of contract acceptor Applies only to contract manufacture and analysis Includes obligations for the contract giver & contract acceptor Not specific to use of QRM Not specific to the need for prior assessment or audit Requires responsibilities to be defined in contract Not specific in terms of requirement for periodic review 14 October 2010 Slide 6

7 Main Principles of ICH Q10 Prior Assessment of the contract acceptor Definition of responsibilities & communication methods Ingredient & material monitoring Monitoring & Review measures 14 October 2010 Slide 7

8 Impact Assessment of Revision to Chapter 7 Additional regulatory burden should be light Technical arrangements for outsourced GMP activities more transparent Clearer & more consistent assessment of outsourced activities Set clearer standards & expectations for industry Harmonised regulatory policy 14 October 2010 Slide 8

9 Implications of Revision to Chapter 7 Extends the range of contracted activities to which Chapter 7 applies Examples of Activities to consider Qualification & Validation Activities QP & Other Professional Services Maintenance & Calibration of Equipment & Premises Storage & archiving 14 October 2010 Slide 9

10 Implications of Revision to Chapter 7 Inclusion of requirements for control over subcontracted operations Mutual Agreement Assessment & On-going Review Contract Giver Prior Assessment Legality Suitability Competence Contract Acceptor On-going Review Records Results Subcontractor Subcontractor 14 October 2010 Slide 10

11 Implications of Revision to Chapter 7 Inclusion of New Requirements for the Contract Communication Processes Subcontracted activities Audit requirement as opposed to visit 14 October 2010 Slide 11

12 Next Steps Review updates Public Consultation before end 2010 GAP Analysis Prepare Strategy Implement Change Points to Consider:- Outsourced Activities not covered under the vendor approval system Review of subcontracting arrangements Review of contracts Points to Consider:- Outsourced Activities not covered under the vendor approval system Review of subcontracting arrangements Prior assessment & Audit obligations Contracts Points to Consider:- Use of change control to implement the strategy 14 October 2010 Slide 12

13 In Summary Current vs. Proposed Contract Manufacture & Analysis Contract Acceptor Outsourced Activities Contract Acceptor & subcontractors Visit Audit 14 October 2010 Slide 13

GMP Track 1 Day 2 Session 1 Vendor Assurance

GMP Track 1 Day 2 Session 1 Vendor Assurance GMP Track 1 Day 2 Session 1 Vendor Assurance 11 August 2015 150403_POUT This session Three presentations Chapter 6 and 7 - Trevor Schoerie Quality Control Out sourced Activities Draft - FDA Quality Metrics

More information

Outsourcing - managing risks and opportunities over which you now have less control

Outsourcing - managing risks and opportunities over which you now have less control Outsourcing - managing risks and opportunities over which you now have less control Kevin O Donnell, PhD PDA Meeting, Dublin 22 nd November 2018 Slide 2 Typical Examples The key GMP Requirements & Guidance

More information

Regulatory Update. Paul Sexton. QP Forum

Regulatory Update. Paul Sexton. QP Forum Regulatory Update Paul Sexton QP Forum 16 th April, 2015 Content Updates on GMP Guidance Updates on EU Legislation Draft Ph Eur monograph on WFI including RO 2 Chapter 5 - Production Paragraphs 27 to 30

More information

Pharmaceutical Quality System (PQS)

Pharmaceutical Quality System (PQS) Implementation of ICH Q8, Q9, Q10 Pharmaceutical Quality System (PQS) International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Structure of

More information

European Union (EU) Regulatory Trends in GMP. Clive Brading Tianjin, China September 23, 2009

European Union (EU) Regulatory Trends in GMP. Clive Brading Tianjin, China September 23, 2009 European Union (EU) Regulatory Trends in GMP Clive Brading Tianjin, China September 23, 2009 -2- Presentation Topics EU Background Inspections outside the EU EMEA Inspection Outcomes Dedicated Facilities

More information

Materials Management Traceability, CEPs and managing non-conforming sites

Materials Management Traceability, CEPs and managing non-conforming sites Materials Management Traceability, CEPs and managing non-conforming sites IMB Information Day, 14 th October 2010 Dr Cormac Dalton Inspector 13-Oct-10 Slide 1 Managing Supply Supply Demand Supply chain

More information

Quality Agreements with CMO s. Presented at ASQ Orange Empire Meeting May 13, 2014 By Luke Foo Sr. Director QA/QC Spectrum Pharmaceuticals

Quality Agreements with CMO s. Presented at ASQ Orange Empire Meeting May 13, 2014 By Luke Foo Sr. Director QA/QC Spectrum Pharmaceuticals Quality Agreements with CMO s Presented at ASQ Orange Empire Meeting May 13, 2014 By Luke Foo Sr. Director QA/QC Spectrum Pharmaceuticals FDA Guidance Contract Manufacturing Arrangements for Drugs: Quality

More information

The APIC Audit Programme Version 5, July 2017

The APIC Audit Programme Version 5, July 2017 The APIC Audit Programme Version 5, July 2017 Table of contents 1 General 2. APIC Audit Programme 3 The Auditors 3.1 Educational Background and Experience 3.2 Auditor Training Courses for Certification

More information

Impacto de las Nuevas Tendencias Regulatorias en la Producción de Parenterales. Innovacion en Packaging Primario

Impacto de las Nuevas Tendencias Regulatorias en la Producción de Parenterales. Innovacion en Packaging Primario Impacto de las Nuevas Tendencias Regulatorias en la Producción de Parenterales Innovacion en Packaging Primario 1 Contents Company Highlight What s Changing in Pharma Pharma Trends Harmonisation New Requirements

More information

Quality Risk Management

Quality Risk Management Implementation of ICH Q8, Q9, Q10 Quality Risk Management International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Introduction Structure of

More information

ICH Quality Implementation Working Group POINTS TO CONSIDER

ICH Quality Implementation Working Group POINTS TO CONSIDER ICH Quality Implementation Working Group POINTS TO CONSIDER ICH-Endorsed Guide for ICH Q8/Q9/Q10 Implementation Document date: 16 June 2011 International Conference on Harmonisation of Technical Requirements

More information

Regulatory Requirements & Recent Changes, including expectations for APIs & IMPs

Regulatory Requirements & Recent Changes, including expectations for APIs & IMPs Regulatory Requirements & Recent Changes, including expectations for APIs & IMPs Neil Raw - GMP Inspector Richard Andrews - Operations Manager 11 th November 2008 Programme: Regulatory Requirements Neil

More information

QUALITY ASSURANCE. Pharma Quality Agreements: What Are They, and Why They Matter For Your Study ABSTRACT

QUALITY ASSURANCE. Pharma Quality Agreements: What Are They, and Why They Matter For Your Study ABSTRACT WHITE PAPER PRESENTED BY PREMIER RESEARCH Pharma Quality Agreements: What Are They, and Why They Matter For Your Study ABSTRACT Quality Agreements are an effective bridge to a successful future for companies

More information

The APIC Audit Programme Version 3, August 2010

The APIC Audit Programme Version 3, August 2010 The APIC Audit Programme Version 3, August 2010 Table of contents 1 General 2. APIC Audit Program 3 The Auditors 3.1 Educational Background and Experience 3.2 Auditor Training Courses for Certification

More information

Wholesaling & Distribution & the GMPs

Wholesaling & Distribution & the GMPs Wholesaling & Distribution & the GMPs Presented by Bryan Wright 11 th July 2016 Overview Wholesaling & distribution of Medicines (FPs) in the EU New EU GDP Guidelines Expectations How complicated can the

More information

Wholesaling & Distribution & the GMPs

Wholesaling & Distribution & the GMPs Wholesaling & Distribution & the GMPs Presented by Bryan Wright 11 th July 2016 Overview Wholesaling & distribution of Medicines (FPs) in the EU New EU GDP Guidelines Expectations How complicated can the

More information

STANDARD OPERATING PROCEDURE

STANDARD OPERATING PROCEDURE Lab. Ofichem B.V. Pag.: 1 / 14 Contents 1. General... 2 2. Scope... 3 3. Definitions and abbreviations... 3 4. Shared Third Party audit program... 3 5. Reassurance absence of Conflict of Interest... 5

More information

New GMPs for Active Substances & Excipients. Presented by Eoin Hanley 4 July, 2016

New GMPs for Active Substances & Excipients. Presented by Eoin Hanley 4 July, 2016 New GMPs for Active Substances & Excipients Presented by Eoin Hanley 4 July, 2016 What we will cover in this session The changing landscape EC Guideline on principles of GDP of active substances Formalised

More information

Trinity College Dublin QP Forum 2017 Tuesday 25 th April

Trinity College Dublin QP Forum 2017 Tuesday 25 th April Trinity College Dublin QP Forum 2017 Tuesday 25 th April HPRA QUESTIONS & ANSWERS 1. What is the approach being taken for audit of contamination control strategies as per chapters 3 & 5? What is the current

More information

1201 Maryland Avenue SW, Suite 900, Washington, DC ,

1201 Maryland Avenue SW, Suite 900, Washington, DC , 1201 Maryland Avenue SW, Suite 900, Washington, DC 20024 202-962-9200, www.bio.org 15 July 2010 European Commission Enterprise and Industry Directorate General Consumer Goods, Pharmaceuticals B-1049 Brussels

More information

EU and FDA GMP Regulations: Overview and Comparison

EU and FDA GMP Regulations: Overview and Comparison THE QUALITY ASSURANCE JOURNAL, VOL. 2, 55 60 (1997) EU and FDA GMP Regulations: Overview and Comparison The increasing emphasis on global supply of drug products, as well as starting materials and investigational

More information

Quality Assessment & GMP Similarities & Differences

Quality Assessment & GMP Similarities & Differences Quality Assessment & GMP Similarities & Differences EMEA, Monday 26 th October 2009 Cormac Dalton Inspector Irish Medicines Board Date 12-Oct-09 Slide 1 Content Overview of commonalities & differences

More information

Working Party on Control of Medicines and Inspections. Final Version of Annex 16 to the EU Guide to Good Manufacturing Practice

Working Party on Control of Medicines and Inspections. Final Version of Annex 16 to the EU Guide to Good Manufacturing Practice Version 8 (final) EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL Single market, regulatory environment, industries under vertical legislation Pharmaceuticals and cosmetics Brussels, July 2001 Working

More information

Regional GMP Strengthening Workshop for Indian Pharmaceutical Manufacturers and State Regulators

Regional GMP Strengthening Workshop for Indian Pharmaceutical Manufacturers and State Regulators Regional GMP Strengthening Workshop for Indian Pharmaceutical Manufacturers and State Regulators Focused on GMP in production of Active Pharmaceutical Ingredients and Oral Solid Dosage Forms Organized

More information

Europe s new approach to assurance of API quality and its implications for manufacturers and producing countries

Europe s new approach to assurance of API quality and its implications for manufacturers and producing countries Europe s new approach to assurance of API quality and its implications for manufacturers and producing countries IPA / EDQM / WHO Mumbai Conference 28 September 2012 Dr Florence Benoit-Guyod, EDQM Inspector,

More information

Vergleich der Versionen von Kapitel 7 des EU-GMP-Leitfadens (September 2012)

Vergleich der Versionen von Kapitel 7 des EU-GMP-Leitfadens (September 2012) (Valid until January 31, Principle Contract manufacture and analysis must be correctly defined, agreed and controlled in order to avoid misunderstandings which could result in a product or work of unsatisfactory

More information

Quality Risk Management. of the GDP Supply Chain. Dr Cormac Dalton Inspector. Crowne Plaza Hotel, 25/2/2010. Date 22-Feb-10 Slide 1

Quality Risk Management. of the GDP Supply Chain. Dr Cormac Dalton Inspector. Crowne Plaza Hotel, 25/2/2010. Date 22-Feb-10 Slide 1 Quality Risk Management of the GDP Supply Chain Crowne Plaza Hotel, 25/2/2010 Dr Cormac Dalton Inspector Date 22-Feb-10 Slide 1 Supply Chain Experiment Pharmaceutical excipient ordered 3 rd December 09

More information

Regulatory Update. Greg McGurk, GMP Manager (acting) GMP Conference. 7 February 2017 Dublin

Regulatory Update. Greg McGurk, GMP Manager (acting) GMP Conference. 7 February 2017 Dublin Regulatory Update Greg McGurk, GMP Manager (acting) GMP Conference 7 February 2017 Dublin GMP Update Chapter 3 - Premises and Equipment (into operation since 1 March 2015) Chapter 5 - Production (into

More information

Cost-effective Purification of Vaccines, Data Integrity Systems and CTDs. DRAFT AGENDA Rio de Janeiro, 18 to 20 June 2018

Cost-effective Purification of Vaccines, Data Integrity Systems and CTDs. DRAFT AGENDA Rio de Janeiro, 18 to 20 June 2018 Cost-effective Purification of Vaccines, Data Integrity Systems and CTDs DRAFT AGENDA Rio de Janeiro, 18 to 20 June 2018 DAY1, Monday 18 June - Welcome & Introduction Plenary session for all participants

More information

GMP GUIDELINES. GMP Guides from Industry Organisations. FDA cgmp WHO GMP. cgmp Guide Drugs 21 CFR 210 GAMP. ISPE Technical Guides

GMP GUIDELINES. GMP Guides from Industry Organisations. FDA cgmp WHO GMP. cgmp Guide Drugs 21 CFR 210 GAMP. ISPE Technical Guides FDA cgmp cgmp Guide Drugs 21 CFR 210 cgmp Guide Drugs 21 CFR 211 cgmp Guide Medical Device 21 CFR 808, 812, 820 cgmp Guide Biologics 21 CFR 600, 606, 610 Guideline List Human Drugs Guideline List Biologics

More information

Supersedes Division Name Revision No. 0 Export Division Page No. 1 of 9

Supersedes Division Name Revision No. 0 Export Division Page No. 1 of 9 Page No. 1 of 9 Control Status 1.0 Purpose To lay down a procedure for conducting GMP inspection and report writing for issue of Written Confirmation for for medicinal products for human. 2.0 Scope This

More information

GMP for ATMP. Advanced Therapy Medicinal Products Key2Compliance AB

GMP for ATMP. Advanced Therapy Medicinal Products Key2Compliance AB GMP for ATMP Advanced Therapy Medicinal Products 2018 Key2Compliance AB 1 Content Background and regualtory requirements GMP Walkthrough Quality Risk Management 2018 Key2Compliance AB 2 Background and

More information

Legislative Framework and Scientific Guidance in European Assessment

Legislative Framework and Scientific Guidance in European Assessment Legislative Framework and Scientific Guidance in European Assessment Riccardo Luigetti Quality Assessors Training London 26 October 2009 1 Content of the presentation Scientific guidelines Other related

More information

GUIDELINES ON THE PRINCIPLES OF GOOD DISTRIBUTION PRACTICE OF ACTIVE SUBSTANCES FOR MEDICINAL PRODUCTS FOR HUMAN USE

GUIDELINES ON THE PRINCIPLES OF GOOD DISTRIBUTION PRACTICE OF ACTIVE SUBSTANCES FOR MEDICINAL PRODUCTS FOR HUMAN USE PHARMACEUTICAL INSPECTION CONVENTION PHARMACEUTICAL INSPECTION CO-OPERATION SCHEME PI 047-1 Annex 1 July 2018 GUIDELINES ON THE PRINCIPLES OF GOOD DISTRIBUTION PRACTICE OF ACTIVE SUBSTANCES FOR MEDICINAL

More information

Work plan for the GMP/GDP Inspectors Working Group for 2017

Work plan for the GMP/GDP Inspectors Working Group for 2017 13 January 2017 EMA/INS/GMP/584202/2016 Work plan for the GMP/GDP Inspectors Working Group for 2017 Chairperson: David Cockburn Adopted: December 2016 1. Meetings scheduled for 2017 Face-to-face meetings

More information

Annex 14 WHO guidelines for drafting a site master file 136

Annex 14 WHO guidelines for drafting a site master file 136 World Health Organization WHO Technical Report Series, No.961, 2011 Annex 14 WHO guidelines for drafting a site master file 136 1. Introduction 2. Purpose 3. Scope 4. Content of site master fi le Appendix

More information

Christian Gausepohl, Frank Böttcher. GMP Focus. Managing Contract Manufacturers and Testing Labs. PDF Download. Excerpt from the GMP MANUAL

Christian Gausepohl, Frank Böttcher. GMP Focus. Managing Contract Manufacturers and Testing Labs. PDF Download. Excerpt from the GMP MANUAL Christian Gausepohl, Frank Böttcher GMP Focus Managing Contract Manufacturers and Testing Labs PDF Download Excerpt from the GMP MANUAL Bibliographic Data of the Deutsche Nationalbibliothek: http://dnb.ddb.de

More information

Impact of EU GMPs on Australian GMP. Trevor Schoerie PharmOut

Impact of EU GMPs on Australian GMP. Trevor Schoerie PharmOut Impact of EU GMPs on Australian GMP Trevor Schoerie PharmOut Part I Basic Requirements for Medicinal Products Current TGA Version, 7 years out of date TGA are actively and publically talking about PE009-0813

More information

Good Distribution Practice and Supply Chain Risk Evaluation

Good Distribution Practice and Supply Chain Risk Evaluation Good Distribution Practice and Supply Chain Risk Evaluation Who we are - Exelsius An international consultancy established in 2007 bringing cross-sector expertise and skills into a range of services designed

More information

Work plan for the GMP/GDP Inspectors Working Group for 2018

Work plan for the GMP/GDP Inspectors Working Group for 2018 30 November 2017 EMA/INS/GMP/504401/2017 Inspections, Human Medicines Pharmacovigilance & Committees Division Work plan for the GMP/GDP Inspectors Working Group for 2018 Chairperson: Brendan Cuddy Adopted:

More information

Impacto de las Nuevas Tendencias Regulatorias en la Producción de Parenterales

Impacto de las Nuevas Tendencias Regulatorias en la Producción de Parenterales Impacto de las Nuevas Tendencias Regulatorias en la Producción de Parenterales Empaques Primarios y Tendencias Farmaceuticas para Inyectables 1 International Support Support in R&D Technology Transfer

More information

Evaluation of Counterfeit Cases Impact of FMD & GDPs. Lorraine Nolan Healthcare Products Distribution Manager

Evaluation of Counterfeit Cases Impact of FMD & GDPs. Lorraine Nolan Healthcare Products Distribution Manager Evaluation of Counterfeit Cases Impact of FMD & GDPs Wholesale Distribution Information Day, 28th September 2012 Lorraine Nolan Healthcare Products Distribution Manager Slide 1 Contents 1. Review of UK

More information

Effective Management and Operations of GXP Laboratories

Effective Management and Operations of GXP Laboratories Effective Management and Operations of GXP Laboratories Course Objective: Upon completion of this course, attendees involved in establishing and assuring that Good Laboratory / Good Manufacturing Practice

More information

Good Manufacturing Practice for ATMPs Rocio Salvador Roldan DG SANTE, Unit B5

Good Manufacturing Practice for ATMPs Rocio Salvador Roldan DG SANTE, Unit B5 Good Manufacturing Practice for ATMPs Rocio Salvador Roldan DG SANTE, Unit B5 This presentation only reflects the views of its author and does not necessarily reflect the opinion of the Commission Overview

More information

Latino America Consultores Innovation & Technology to make your Business Compliant

Latino America Consultores Innovation & Technology to make your Business Compliant Latino America Consultores Innovation & Technology to make your Business Compliant Annex 15 & EMA Process Validation Guide Line 1 Changes in Requirements The Pharmaceutical Industry has adapted its business

More information

Cold Chain Committee Guidance for shippers, transport service providers and subcontractors

Cold Chain Committee Guidance for shippers, transport service providers and subcontractors Guidance for shippers, transport service providers and subcontractors involved in the distribution of pharmaceutical products registered for storage between 2 and 8 Celsius Guidance for Shippers 1 of 7

More information

Textvergleich. Verglichene Dokumente MEDIA3917.pdf. ICH_Q10_Step4.pdf

Textvergleich. Verglichene Dokumente MEDIA3917.pdf. ICH_Q10_Step4.pdf Textvergleich Verglichene Dokumente MEDIA3917.pdf ICH_Q10_Step4.pdf Übersicht 2270 Wort/Wörter hinzugefügt 1338 Wort/Wörter gelöscht 3558 Wort/Wörter übereinstimmend 157 Block/Blöcke übereinstimmend Blättern

More information

GMP for ATMPs. Ian Rees, Unit Manager Inspectorate Strategy & Innovation 4 th October 2018

GMP for ATMPs. Ian Rees, Unit Manager Inspectorate Strategy & Innovation 4 th October 2018 GMP for ATMPs Ian Rees, Unit Manager Inspectorate Strategy & Innovation 4 th October 2018 Presentation outline MHRA Annex 2-2013 Change procedure for GMP guidelines Part IV EU & PIC/S MHRA/BP/NIBSC - standards

More information

" NATIONALLY AND INTERNATIONALLY AT THE HIGHEST LEVEL." Audit

 NATIONALLY AND INTERNATIONALLY AT THE HIGHEST LEVEL. Audit " NATIONALLY AND INTERNATIONALLY AT THE HIGHEST LEVEL." Audit " NATIONALLY AND INTERNATIONALLY AT THE HIGHEST LEVEL." pharmaplace AG EXPLOITING POTENTIALS TOGETHER " Since 2009, we have had GMP audits

More information

Advantages, Opportunities & Challenges of Adopting the Post Approval Change Management Plan (PACMP)

Advantages, Opportunities & Challenges of Adopting the Post Approval Change Management Plan (PACMP) Advantages, Opportunities & Challenges of Adopting the Post Approval Change Management Plan (PACMP) Quality Forum September 2018 roger nosal, Vice President & Head Worldwide Safety & Regulatory - Global

More information

PHARMA KNOWLEDGE PARK

PHARMA KNOWLEDGE PARK GUIDELINES 2013 WWW.NOORMD.COM A COMPILATION BY ON PHARMACEUTICAL REGULATORY GUIDELINES INTRODUCED / REVISED DURING THE YEAR 2013. Page 2 ICH Assessment and control of DNA reactive (mutagenic) impurities

More information

Christine Oechslein. GMP Focus. Managing Process Validation. A Drugmaker s Guide. PDF Download. Excerpt from the GMP MANUAL

Christine Oechslein. GMP Focus. Managing Process Validation. A Drugmaker s Guide. PDF Download. Excerpt from the GMP MANUAL Christine Oechslein GMP Focus Managing Process Validation A Drugmaker s Guide PDF Download Excerpt from the GMP MANUAL Bibliographic Data of the Deutsche Nationalbibliothek: http://dnb.ddb.de ISBN: 978-3-95807-056-1

More information

Electronic Systems - Regulators Observations

Electronic Systems - Regulators Observations Electronic Systems - Regulators Observations Catherine Neary QP Forum Trinity College Dublin, 16 th April 2015 Agenda Introduction to Topic Data Integrity Considerations for any Electronic System Summary

More information

Good Clinical Practice (GCP): how does a laboratory that supports a clinical trial ensure compliance with these Regulations

Good Clinical Practice (GCP): how does a laboratory that supports a clinical trial ensure compliance with these Regulations Good Clinical Practice (GCP): how does a laboratory that supports a clinical trial ensure compliance with these Regulations 9th edition of Synevo Clinical Research Symposium. 17 th November 2017 Bucharest.

More information

Lessons from Pharmaceutical Laboratory related FDA Warning Letters

Lessons from Pharmaceutical Laboratory related FDA Warning Letters Lessons from Pharmaceutical Laboratory related FDA Warning Letters The Agilent Critical Compliance Seminar 2016 Ludwig Huber Ludwig_huber@labcompliance.com Overview FDA Inspections and reports GMP compliance

More information

DECEMBER 2008 GUIDANCE NOTES ON PRODUCT QUALITY REVIEW

DECEMBER 2008 GUIDANCE NOTES ON PRODUCT QUALITY REVIEW DECEMBER 2008 GUIDANCE NOTES ON PRODUCT QUALITY REVIEW 1.0 INTRODUCTION: The purpose of this guidance is to communicate the expectation with regard to the conduct of Product Quality Review. Product Quality

More information

Common deficiencies/ hot topics

Common deficiencies/ hot topics Common deficiencies/ hot topics Non-sterile & API manufacture Oisín Daly GMP Conference 7 February 2017 Dublin Non-sterile finished product manufacture Deficiencies by Eudralex Vol. 4 GMP guide > 60% 3

More information

International Supply Chain: How are we handling globalisation? GCP oversight

International Supply Chain: How are we handling globalisation? GCP oversight International Supply Chain: How are we handling globalisation? GCP oversight Susana Almeida, PhD Senior Director, European Operations Inflamax Research (Canada) patients quality value sustainability partnership

More information

FDA Quality Metrics, Data Integrity and Application of Statistics Throughout Process Validation in a Global Economy

FDA Quality Metrics, Data Integrity and Application of Statistics Throughout Process Validation in a Global Economy CBI Statistics in Validation FDA Quality Metrics, Data Integrity and Application of Statistics Throughout Process Validation in a Global Economy Jerry Lanese Ph.D. The Lanese Group, Inc. 2017 The Lanese

More information

Inspection of API Manufacturers & Update on Registration Process

Inspection of API Manufacturers & Update on Registration Process Inspection of API Manufacturers & Update on Registration Process Catherine Neary, GMP Inspector GMP Conference 7 February 2017 Dublin Presentation Contents HPRA Inspection Programme for API Manufacturers

More information

New EU GMP for ATMPs vs existing GMPs pros and cons. Drew Hope Director of Quality Operations, Autolus

New EU GMP for ATMPs vs existing GMPs pros and cons. Drew Hope Director of Quality Operations, Autolus New EU GMP for ATMPs vs existing GMPs pros and cons Drew Hope Director of Quality Operations, Autolus Rapid implementation The EC adopted GMP requirements for ATMPs 22 NOV 2017 Comes into operation 22

More information

Excipient Certification Scheme

Excipient Certification Scheme Excipient Certification Scheme CPhI Breakfast Briefings Feria de Madrid, 13 th October 2009 Dr Arnulf Heubner Member of the EFCG-Board and Chairman of the Pharmaceutical Business Committee (PBC) Excipient

More information

Standard Operating Procedure. Vendor Management

Standard Operating Procedure. Vendor Management REFERENCE: VERSION NUMBER: 2.0 EFFECTIVE DATE: 28-03-18 REVIEW DATE: 28-03-20 AUTHOR: Clinical Trials Manager, Contracts & Quality Management Officer REVIEWED BY: Research & Innovation Group APPROVED BY:

More information

Understanding the requirements of EU food contact legislation

Understanding the requirements of EU food contact legislation Understanding the requirements of EU food contact legislation Dr. Annette Schäfer Head of Sector Food Contact Materials DG SANCO The content of this lecture does not necessarily represent the position

More information

Excipients Facing Increased Scrutiny How to Use Secondary Reference Standards to Help Maintain Regulatory Compliance

Excipients Facing Increased Scrutiny How to Use Secondary Reference Standards to Help Maintain Regulatory Compliance Excipients Facing Increased Scrutiny How to Use Secondary Reference Standards to Help Maintain Regulatory Compliance by Tom Savage, NSF International Since 2008, when patient deaths were first linked to

More information

Quality Risk Management (QRM) of active pharmaceutical ingredients during transportation by using FMEA tools and methodology

Quality Risk Management (QRM) of active pharmaceutical ingredients during transportation by using FMEA tools and methodology PharmaTutor PRINT ISSN: 294-6679 E-ISSN: 247-788 2 Quality Risk Management (QRM) of active pharmaceutical ingredients during transportation by using FMEA tools and methodology Upendra Kumar Singh*, Sammer

More information

GDP for APIs New Regulations. we prove it. The Shift to Monitoring BioPharma Product Quality Throughout Their Lifecycle

GDP for APIs New Regulations. we prove it. The Shift to Monitoring BioPharma Product Quality Throughout Their Lifecycle 1 - Temperature Control Challenges - Full Lifecycle Monitoring WHITE PAPER GDP for APIs New Regulations The Shift to Monitoring BioPharma Product Quality Throughout Their Lifecycle we prove it. 2 GDP for

More information

QS, GDP (+GMP?) Maintaining the Integrity of The Supply Chain

QS, GDP (+GMP?) Maintaining the Integrity of The Supply Chain QS, GDP (+GMP?) Maintaining the Integrity of The Supply Chain Presented by: Karen Ginsbury For IFF 01 March, 2017 Pharma Supply Chain Manufacturer Wholesaler Raw Material Supply Production Transport Warehouse

More information

Good Distribution Practices Toolkit Change Control 10 March 2016

Good Distribution Practices Toolkit Change Control 10 March 2016 Good Distribution Practices Toolkit Change Control 10 March 2016 1 Disclaimer The content of this presentation were derived mainly from WHO training material on Change Control and edited to suit the Distributor

More information

LEGAL REQUIREMENTS and DATA INTEGRITY...

LEGAL REQUIREMENTS and DATA INTEGRITY... LEGAL REQUIREMENTS and DATA INTEGRITY... 1 1 DI Guidances MHRA GMP DI Definitions & Guidance for Industry, March 2015 Guidance on Good Data & Record Management, March, 2016 Data Integrity and Compliance

More information

Risk Based Validation. Why, How and with what tools?

Risk Based Validation. Why, How and with what tools? Risk Based Validation Why, How and with what tools? Tech Talk Agenda History of FDA GMP initiative for the 21 st Century. Industry response to FDA initiative. Harmonisation through ICH. ASTM Standard on

More information

Guideline on good pharmacovigilance practices (GVP)

Guideline on good pharmacovigilance practices (GVP) 1 2 3 19 June 2012 EMA/119871/2012 4 5 Guideline on good pharmacovigilance practices (GVP) Module III Pharmacovigilance inspections Draft finalised by the Agency in collaboration with Member States and

More information

Regulations and guidance for the pharmaceutical industry

Regulations and guidance for the pharmaceutical industry w w w. spec troscopyonline. com April 2011 Spectroscopy 26(4) 1 Focus on Quality Is GMP Annex 11 Europe s Answer to 21 CFR 11? January 2011 saw the publication of the new revision of European Union (EU)

More information

Qualified Persons in the Pharmaceutical Industry. Code of Practice. March 2008

Qualified Persons in the Pharmaceutical Industry. Code of Practice. March 2008 Qualified Persons in the Pharmaceutical Industry Code of Practice March 2008 Updated October 2009 Code of Practice for Qualified Persons 1. INTRODUCTION... 1 2. REGULATORY BASIS FOR THE QUALIFIED PERSON...

More information

Quality Risk Management: Excipients

Quality Risk Management: Excipients Quality Risk Management: Excipients ExcipientFest 2012 Presented by: Londa Ritchey, M.S. Director, Supplier Qualification Global Quality Operations Pfizer, Inc. Agenda Regulatory Environment Material Quality

More information

Hetero Drugs Limited

Hetero Drugs Limited Global Challenges in Quality Assurance of APIs The Perspective of Indian Manufacturers Slide 1 of 30 1 Slide 2 of 30 2 Laws Governing GMPs/Quality United States Food, Drugs and Cosmetics Act Europe European

More information

EMA perspective on Quality Metrics

EMA perspective on Quality Metrics EMA perspective on Quality Metrics Indian Pharmaceutical Alliance Annual Congress, Mumbai India Presented by Brendan Cuddy on 24 February 2017 Head of Manufacturing and Quality Compliance, European Medicines

More information

Session 4: Quality Defect Investigations and Product Recalls

Session 4: Quality Defect Investigations and Product Recalls Session 4: Quality Defect Investigations and Product Recalls Amy Kelly Ph.D. and Kevin O Donnell Ph.D. GMP Conference 12 th November 2014 Outline The application of QRM principles to QD investigations

More information

Pharmaceutical quality requirements

Pharmaceutical quality requirements Pharmaceutical quality requirements through development to commercial medicinal product December 4, 2014 Karin Walhagen Biomedicine the Profession Biomedicine Master Program at Lund University Patient

More information

PHARMACEUTICAL COMMITTEE SUMMARY RECORD 60 th meeting, 2 nd May 2006

PHARMACEUTICAL COMMITTEE SUMMARY RECORD 60 th meeting, 2 nd May 2006 EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL Consumer goods Pharmaceuticals PHARM 529 PHARMACEUTICAL COMMITTEE SUMMARY RECORD 60 th meeting, 2 nd May 2006 OPENING Mr Martin Terberger,

More information

QP s experience with QRM. Fergus O Connell QA Manager AMS Laboratories

QP s experience with QRM. Fergus O Connell QA Manager AMS Laboratories QP s experience with QRM Fergus O Connell QA Manager AMS Laboratories December 2011 Risk Management in a QPs role Validation Master Plan Risk Review Early issues Human Error Risk Influencing Factors EU

More information

Inspection. Implementation of ICH Q8, Q9, Q10

Inspection. Implementation of ICH Q8, Q9, Q10 Implementation of ICH Q8, Q9, Q10 International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Outline Aim of - as a key part of the regulatory

More information

EUROPEAN INDUSTRIAL PHARMACISTS GROUP. Guidance on CPD for QUALIFIED PERSONS

EUROPEAN INDUSTRIAL PHARMACISTS GROUP. Guidance on CPD for QUALIFIED PERSONS EUROPEAN INDUSTRIAL PHARMACISTS GROUP Guidance on CPD for QUALIFIED PERSONS EIPG Guidance on CPD for QP Continuing Professional Development for Qualified Persons, Technical Directors and other Responsible

More information

The European Commission's Proposal to Re-design Existing European Drug Safety Rules. An Industry View on Practical Implications

The European Commission's Proposal to Re-design Existing European Drug Safety Rules. An Industry View on Practical Implications The European Commission's Proposal to Re-design Existing European Drug Safety Rules An Industry View on Practical Implications Margaret Walters Merck, Sharp & Dohme Ltd. The Second International Pharmaceutical

More information

Challenges in Implementing Knowledge Management within ICH Q10

Challenges in Implementing Knowledge Management within ICH Q10 Challenges in Implementing Knowledge Management within ICH Q10 SYMPOSIUM - New Frontiers in Manufacturing Technology, Regulatory - Brasilia Joseph C. Famulare Vice President, Global Head Compliance and

More information

API Inspections in Emerging Markets: The EDQM Experience

API Inspections in Emerging Markets: The EDQM Experience API Inspections in Emerging Markets: The EDQM Experience 18 October 2010 Sträter Life Science Gründungsymposium Dr Florence Benoit-Guyod, EDQM Inspector Certification of Substances Division European Directorate

More information

Good Manufacturing Practices Purpose and Principles of GMP. Tony Gould

Good Manufacturing Practices Purpose and Principles of GMP. Tony Gould Good Manufacturing Practices Purpose and Principles of GMP Tony Gould Why GMP? Provides a high level assurance that medicines are manufactured in a way that ensures their safety, efficacy and quality Medicines

More information

QUALITY AGREEMENT. The following Agreement has been concluded between

QUALITY AGREEMENT. The following Agreement has been concluded between QUALITY AGREEMENT The following Agreement has been concluded between LLC LABORATORIES The contract laboratory and service provider 1625 Trinity Dr., Unit 11 Mississauga, Ontario Canada L5T 1W9 Hereinafter

More information

CDER Perspective: Good Clinical Practice

CDER Perspective: Good Clinical Practice CDER Perspective: Good Clinical Practice Sensible Guidelines Symposium, 25 May 2012 Ann Meeker-O Connell FDA, CDER, Office of Compliance Office of Scientific Investigations The views presented in this

More information

Re: PCIM/11/01 Public Consultation on Implementing Measures for Pharmacovigilance

Re: PCIM/11/01 Public Consultation on Implementing Measures for Pharmacovigilance 07 November 2011 By email: sanco pharmaceuticals@ec.europa.eu Directorate General for Health and Consumers Unit SANCO/D/3 BE 1049 Brussels Belgium Dear Sirs, Re: PCIM/11/01 Public Consultation on Implementing

More information

GMP for ATMP should be a document annexed to standard GMP (a new Annex) and not a stand-alone document.

GMP for ATMP should be a document annexed to standard GMP (a new Annex) and not a stand-alone document. Leem comments on Commission proposal for Good Manufacturing Practice for Advanced Therapy Medicinal Products 1. General comments Line number(s) of the relevant text General comment

More information

Task, View and Values

Task, View and Values Task, View and Values TASK VIEW VALUES We help to analyze, improve and validate the key business processes of our clients, through our own methodology, so we can guarantee the quality, the efficiency and

More information

Current Global GMP Status and Trends With Focus on EU & PIC/S JPMA Annual Meeting, Tokyo & Osaka, September 2012 Dr.-Ing.

Current Global GMP Status and Trends With Focus on EU & PIC/S JPMA Annual Meeting, Tokyo & Osaka, September 2012 Dr.-Ing. Current Global GMP Status and Trends With Focus on EU & PIC/S JPMA Annual Meeting, Tokyo & Osaka, September 2012 Dr.-Ing. Stephan Rönninger Pharma Medicines Technical Operations Global Quality & Compliance,

More information

While the recognition

While the recognition Designing the Perfect Change Control System Change control systems today are expected to be designed in a way that provides a system to not only document and approve changes, but also to anticipate change

More information

School of Pharmacy & Pharmaceutical Sciences QP Forum Thursday 16th April McGee Pharma International

School of Pharmacy & Pharmaceutical Sciences QP Forum Thursday 16th April McGee Pharma International School of Pharmacy & Pharmaceutical Sciences QP Forum Thursday 16th April 1 Parallel Session - Sterile Facilitator Ms Ann McGee 2 Query Topics Contamination Control Strategy Problems virtually managing

More information

Data Integrity Why is it important? DADM Conference - 22 August 2017

Data Integrity Why is it important? DADM Conference - 22 August 2017 Data Integrity Why is it important? DADM Conference - 22 August 2017 Maibritt Haugaard Møller, System Validation Expert Mette Ravn, Vice President, Data Management, IT and System Validation Overview of

More information

Computerised Systems. Inspection Expectations. Paul Moody, Inspector. 18/10/2013 Slide 1. ISPE GAMP COP Ireland Meeting, Dublin, 17 th October 2013

Computerised Systems. Inspection Expectations. Paul Moody, Inspector. 18/10/2013 Slide 1. ISPE GAMP COP Ireland Meeting, Dublin, 17 th October 2013 Computerised Systems Inspection Expectations ISPE GAMP COP Ireland Meeting, Dublin, 17 th October 2013 Paul Moody, Inspector Slide 1 Presentation Contents Brief Introduction to the IMB Regulatory References

More information

Plasma for Fractionation

Plasma for Fractionation www.pei.de Plasma for Fractionation Regulatory & Quality Standards in the EU Dr. Sabine Wegehaupt Inspection Services for Biological Medicinal Products IPFA Workshop Stellenbosch December 01-02, 2015 Plasma

More information

Comments from: 1. General comments. International Plasma Fractionation Association (IPFA) Our ref. IP

Comments from: 1. General comments. International Plasma Fractionation Association (IPFA) Our ref. IP Submission of comments on Commission proposal for Good Manufacturing Practice for Advanced Therapy Medicinal Products Comments from: Name of organisation or individual International

More information

ICH Q12 (Pharmaceutical Product Lifecycle Management): PMDA Perspective

ICH Q12 (Pharmaceutical Product Lifecycle Management): PMDA Perspective ISPE Japan Affiliate 2016 Annual Meeting, April 14-15, 2016, Tower hall Funabori, Tokyo, Japan ICH Q12 (Pharmaceutical Product Lifecycle Management): PMDA Perspective Yasuhiro Kishioka, Ph.D. Principal

More information